ロード中...
Acute onset of fingolimod-associated macular edema
PURPOSE: Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular ede...
保存先:
| 出版年: | Am J Ophthalmol Case Rep |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5757484/ https://ncbi.nlm.nih.gov/pubmed/29503930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajoc.2016.09.005 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|